Posts

One-year data of bimekizumab versus ustekinumab for plaque psoriasis in the BE VIVID trial

One-year data of bimekizumab versus ustekinumab for plaque psoriasis in the BE VIVID trial

One-year data of bimekizumab versus ustekinumab for plaque psoriasis in the BE VIVID trial

FDA approves daratumumab plus VMP for transplant ineligible myeloma patients

 

On 7 May 2018 the US FDA approved daratumumab (DARZALEX®) in combination with the VMP regimen (bortezomib (VELCADE®), melphalan, and prednisone) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Ribociclib FDA label updated to include pre- and perimenopausal women

FDA approves apalutamide for non-metastatic castration-resistant prostate cancer

 

  • FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. More Information.

FDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk CSPC

 

  • FDA approved abiraterone acetate (Zytiga, Janssen Biotech Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). More Information.